LCM
TYRA icon

Legato Capital Management’s Tyra Biosciences TYRA Stock Holding History

Legato Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,259
Closed -$332K – 626
2024
Q1 		$332K Buy
+20,259
New +$332K 0.04% 496

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Legato Capital Management's TYRA Position: Q2 2024 in Review

Legato Capital Management sold out of Tyra Biosciences (TYRA) in Q2 2024, closing a stake of 20,259 shares — an estimated $332K sold.

Legato Capital Management first reported a position in TYRA in Q1 2024 and held it in 1 quarter. The position peaked at $332K in Q1 2024. 79 funds tracked by Wall St. Rank hold TYRA as of Q2 2024.

  • Legato Capital Management reported no remaining Tyra Biosciences position as of Q2 2024 after selling out during the quarter.
  • Legato Capital Management sold 20,259 Tyra Biosciences shares in Q2 2024, an estimated $332K.
  • Legato Capital Management first reported a position in Tyra Biosciences in Q1 2024 and held it in 1 quarter.
  • Legato Capital Management's Tyra Biosciences position peaked at $332K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2024.

Based on Legato Capital Management's 13F filing for Q2 2024, filed 26 Jul 2024.